Spectrum Pharmaceuticals, Inc. Release: Phase 2 Trial of Belinostat, a Novel HDAC Inhibitor, in the Treatment of Carcinoma of Unknown Primary (CUP) Meets Enrollment Target

IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGM: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the target enrollment has been reached for the Phase 2 study of belinostat in Carcinoma of Unknown Primary (CUP). The study, which is being conducted and fully funded by Spectrum’s partner, Topotarget A/S, is an open-label, randomized, controlled Phase 2 study in which patients with previously untreated CUP, were randomized into one of two treatment arms: Belinostat + carboplatin and paclitaxel (BelCaP), or carboplatin and paclitaxel (CaP). The primary objective of the CUP study is to provide an estimate of the treatment effect of BelCaP compared to CaP in terms of progression-free survival, response rate, and overall survival in patients with CUP.